GAO’s Plan B Report Expected In November
This article was originally published in The Pink Sheet Daily
Executive Summary
Separately, a federal judge schedules a Dec. 16 hearing on the Center for Reproductive Rights’ lawsuit against FDA over its handling of the Rx-to-OTC switch application.
You may also be interested in...
FDA Staff Accounts Conflict On Plan B Decision Timeline, GAO Report Finds
Office of New Drugs officials contend they were told the over-the-counter switch application for Barr's emergency contraceptive would be denied following a positive advisory committee review, but Center for Drug Evaluation & Research officials deny the decision was made before the letter was sent.
Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products
FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation